Canada markets close in 5 hours 47 minutes

KALV Sep 2024 7.500 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.30000.0000 (0.00%)
As of 11:37AM EDT. Market open.
Full screen
Previous Close0.3000
Open0.3000
Bid0.0000
Ask0.7500
Strike7.50
Expire Date2024-09-20
Day's Range0.3000 - 0.3000
Contract RangeN/A
Volume3
Open Interest8
  • Business Wire

    KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

    CAMBRIDGE, Mass. & SALISBURY, England, June 18, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older.

  • Business Wire

    KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

    CAMBRIDGE, Mass. & SALISBURY, England, June 06, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented the US subgroup analysis from the sebetralstat phase 3 KONFIDENT trial and real-world claims and patient survey data at the Eastern Allergy Conference (EAC) 2024, as well as the Japanese subgroup from KONFIDENT at the 123rd Annual Meeting of the Japanese Dermatological Association (JDA) 2024. KONFIDENT is the first pivotal phase 3 trial to include Japanese sites

  • Business Wire

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass. & SALISBURY, England, June 04, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on June 3, 2024 as inducement material to such employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).